文档介绍：抑那通治疗前列腺癌的新进展
AUA(2010)内分泌治疗新进展
METHODS
A group of 157 patients were enrolled in this interim analysis of a prospec) and cholesterol.
AUA(2010)内分泌治疗新进展
RESULTS
ADT
Control
P
N
148
100
Fat thickness(mm)

<
BMD=bone mineral density

<
BMI (kg/m2)

<
There are no significant changes in hemoglobin and cholesterol levels.
AUA(2010)内分泌治疗新进展
CONCLUSION
Our results show that Korean men with prostate cancer have increased abdominal subcutaneous fat and BMI and have decreased BMD during androgen deprivation therapy.
These increases the risk of bone fracture and complication related obesity. Therefore, BMD will be checked periodically and carry out exercise program to prevention obesity during androgen deprivation therapy.
AUA(2010)内分泌治疗新进展
Sarcopenia in men receiving androgen deprivation therapy for prostate cancer: a prospective 3-year study.
Matthew R. Smith,CA.
AUA(2010)内分泌治疗新进展
INTRODUCTION AND OBJECTIVES
Androgen deprivation therapy (ADT) for prostate cancer decreases bone mineral density and increases fracture risk.
Studies with limited sample size and observational periods have reported that ADT is also associated with sarcopenia or loss of muscle (lean body mass, LBM).
We now report the prospective changes in LBM in a subset of men from that study.
AUA(2010)内分泌治疗新进展
METHODS
Men undergoing ADT for nonmetastatic prostate cancer at 38 centers in North America were randomized to denosumab or placebo.
A total of 248 subjects (130 denosumab, 118 placebo) with a baseline and with at least 1 on-study LBM result were considered evaluable and included in this analysis.
AUA(2010)内分泌治疗新进展
METHODS
Subjects were stratified at baseline by age (<70 years vs ≥70 years) and by duration of ADT treatment (≤6 months vs >6 months).
LBM was measured by total body dual-energy x-ray absorptiometry at baseline and at 12, 24, and 36 months.
AUA(2010)内分泌治疗新进展
RESULTS
From baseline to month 12, mean LBM